Touchstone
Last syncNov 1, 2026, 6:55 PM ET

TRAX

First Tracks Biotherapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$45.08Close $15.32 – $47.9252-week range Nov 11, 2026Next report

Highlights

Cautions

  • Results soon Nov 11, 2026, in 10 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 26, 2026
Off 12-month high 6%
1wk up 2.3% price change
1mo up 27.2% price change
12-month return up 137% total, dividends included
F-score — — Not assessed
Altman Z — Unknown
P/E — price / earnings
PEG — P/E / EPS growth
P/B — price / book
Earnings yield — EBIT / enterprise value
Cheaper than — of the market · not assessed
Revenue growth — year on year
EPS growth — latest quarter
Sales growth — latest quarter
ROE down 49% return on equity
Free cash margin — -$143.0M FCF
D/E — long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest

Trade setup

ATR% 6.9% $3.10 a day · 2×ATR $38.88
RS — vs the universe
Trend — trend template
Relative volume 0.5× vs 50-day average
Up/down volume 1.38 50 sessions
Implied move — no option chain · report Nov 11, 2026

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Aug 12, 2026
Results reaction Aug 12, 2026-7% vs market2 sessions after results

Financials

2 fiscal years · from filings
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$166.1M
-$200M $0 FY24 FY25 FY2024 · -$163.7M FY2025 · -$166.1M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$143.0M
-$200M $0 FY24 FY25 FY2024 · -$126.2M FY2025 · -$143.0M
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $250M FY24 FY25 FY2024 · Cash $123.1M FY2025 · Cash $238.2M
  FY2024Dec 31, 2024 FY2025Dec 31, 2025
Operating income -$181.1M -$179.0M
Net income -$163.7M -$166.1M
Free cash flow -$126.2M -$143.0M
Cash $123.1M $238.2M
Shareholders' equity $391.6M $287.5M
Shares outstanding — 0